The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of personalized medicine 2014-03, Vol.4 (1), p.52-64
Hauptverfasser: Kaufman, Howard L, Wong, Michael K, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Format: Artikel
Sprache:eng
Schlagworte:
Precision medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 64
container_issue 1
container_start_page 52
container_title Journal of personalized medicine
container_volume 4
creator Kaufman, Howard L
Wong, Michael K
Daniels, Gregory A
McDermott, David F
Aung, Sandra
Lowder, James N
Morse, Michael A
description Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.
doi_str_mv 10.3390/jpm4010052
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4251407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1643405212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-6c8e6601a338d4996704bd4ecdf4341af7b821db61835dbe12e0965fa0312c253</originalsourceid><addsrcrecordid>eNpdkV9LHDEUxYNUVKwv_QAS6IsVpk1u_uxMHwqyre3C0payPofMzB0368xkTTIWv30ja9X2vuSS_HI4nEPIG87eC1GxD5vtIBlnTMEeOQI2U4WUoF-92A_JSYwblqdUAJodkENQSgOXcESm1RrpVUTqO_oLr11MwWGkydPFsA3-Duncjg0Gugpo04Bj-kgv6HebnB9tTz_bZGubv3c-0J_5NgNxx2JLf7u0posxYehxunFjAfRssSzg3Wuy39k-4snjeUyuLr-s5t-K5Y-vi_nFsmgk06nQTYlaM26FKFtZVXrGZN1KbNpOCsltN6tL4G2teSlUWyMHZJVWnWWCQwNKHJNPO93tVA_YNtldsL3ZBjfYcG-8debfl9GtzbW_MxIUl2yWBc4eBYK_nTAmM7jYYN_bEf0UDdfZSM6eQ0bf_odu_BRySJlSoKoMSp2p8x3VBB9jwO7JDGfmoVDzXGiGT1_af0L_1if-AAZjmfg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1525943446</pqid></control><display><type>article</type><title>The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Kaufman, Howard L ; Wong, Michael K ; Daniels, Gregory A ; McDermott, David F ; Aung, Sandra ; Lowder, James N ; Morse, Michael A</creator><creatorcontrib>Kaufman, Howard L ; Wong, Michael K ; Daniels, Gregory A ; McDermott, David F ; Aung, Sandra ; Lowder, James N ; Morse, Michael A</creatorcontrib><description>Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm4010052</identifier><identifier>PMID: 25562142</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Precision medicine</subject><ispartof>Journal of personalized medicine, 2014-03, Vol.4 (1), p.52-64</ispartof><rights>Copyright MDPI AG 2014</rights><rights>2014 by the authors; licensee MDPI, Basel, Switzerland. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-6c8e6601a338d4996704bd4ecdf4341af7b821db61835dbe12e0965fa0312c253</citedby><cites>FETCH-LOGICAL-c406t-6c8e6601a338d4996704bd4ecdf4341af7b821db61835dbe12e0965fa0312c253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251407/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251407/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25562142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaufman, Howard L</creatorcontrib><creatorcontrib>Wong, Michael K</creatorcontrib><creatorcontrib>Daniels, Gregory A</creatorcontrib><creatorcontrib>McDermott, David F</creatorcontrib><creatorcontrib>Aung, Sandra</creatorcontrib><creatorcontrib>Lowder, James N</creatorcontrib><creatorcontrib>Morse, Michael A</creatorcontrib><title>The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.</description><subject>Precision medicine</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkV9LHDEUxYNUVKwv_QAS6IsVpk1u_uxMHwqyre3C0payPofMzB0368xkTTIWv30ja9X2vuSS_HI4nEPIG87eC1GxD5vtIBlnTMEeOQI2U4WUoF-92A_JSYwblqdUAJodkENQSgOXcESm1RrpVUTqO_oLr11MwWGkydPFsA3-Duncjg0Gugpo04Bj-kgv6HebnB9tTz_bZGubv3c-0J_5NgNxx2JLf7u0posxYehxunFjAfRssSzg3Wuy39k-4snjeUyuLr-s5t-K5Y-vi_nFsmgk06nQTYlaM26FKFtZVXrGZN1KbNpOCsltN6tL4G2teSlUWyMHZJVWnWWCQwNKHJNPO93tVA_YNtldsL3ZBjfYcG-8debfl9GtzbW_MxIUl2yWBc4eBYK_nTAmM7jYYN_bEf0UDdfZSM6eQ0bf_odu_BRySJlSoKoMSp2p8x3VBB9jwO7JDGfmoVDzXGiGT1_af0L_1if-AAZjmfg</recordid><startdate>20140307</startdate><enddate>20140307</enddate><creator>Kaufman, Howard L</creator><creator>Wong, Michael K</creator><creator>Daniels, Gregory A</creator><creator>McDermott, David F</creator><creator>Aung, Sandra</creator><creator>Lowder, James N</creator><creator>Morse, Michael A</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140307</creationdate><title>The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)</title><author>Kaufman, Howard L ; Wong, Michael K ; Daniels, Gregory A ; McDermott, David F ; Aung, Sandra ; Lowder, James N ; Morse, Michael A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-6c8e6601a338d4996704bd4ecdf4341af7b821db61835dbe12e0965fa0312c253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Precision medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaufman, Howard L</creatorcontrib><creatorcontrib>Wong, Michael K</creatorcontrib><creatorcontrib>Daniels, Gregory A</creatorcontrib><creatorcontrib>McDermott, David F</creatorcontrib><creatorcontrib>Aung, Sandra</creatorcontrib><creatorcontrib>Lowder, James N</creatorcontrib><creatorcontrib>Morse, Michael A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaufman, Howard L</au><au>Wong, Michael K</au><au>Daniels, Gregory A</au><au>McDermott, David F</au><au>Aung, Sandra</au><au>Lowder, James N</au><au>Morse, Michael A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2014-03-07</date><risdate>2014</risdate><volume>4</volume><issue>1</issue><spage>52</spage><epage>64</epage><pages>52-64</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>25562142</pmid><doi>10.3390/jpm4010052</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2075-4426
ispartof Journal of personalized medicine, 2014-03, Vol.4 (1), p.52-64
issn 2075-4426
2075-4426
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4251407
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central
subjects Precision medicine
title The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T18%3A04%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Use%20of%20Registries%20to%20Improve%20Cancer%20Treatment:%20A%20National%20Database%20for%20Patients%20Treated%20with%20Interleukin-2%20(IL-2)&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Kaufman,%20Howard%20L&rft.date=2014-03-07&rft.volume=4&rft.issue=1&rft.spage=52&rft.epage=64&rft.pages=52-64&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm4010052&rft_dat=%3Cproquest_pubme%3E1643405212%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1525943446&rft_id=info:pmid/25562142&rfr_iscdi=true